A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion
Recruiting · Phase 2, Phase 3 · NCT07063745
Conditions: Metastatic Non-small Cell Lung Cancer With MTAP Deletion
At a glance
- Research payments reported, 2025
- $9,307
- U.S. investigators named
- 7
- Sites paid
- 7
- Planned or actual enrollment
- 590
About the trial
- Sponsor
- Bristol-Myers Squibb
- Tested
- BMS-986504 (drug), Pembrolizumab (drug), Placebo (other), Cisplatin (drug), Carboplatin (drug), Pemetrexed (drug), Paclitaxel (drug), Nab-paclitaxel (drug)
- Dates
- Started 2026-01-02; completion 2031-08-12
- Results posted
- Not yet
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemotherapy in first-line metastatic non-small cell lung cancer participants with homozygous MTAP deletion
From ClinicalTrials.gov, last updated 2026-10-23. Full record, eligibility and contacts (opens in a new tab)
Industry funding
E.r. Squibb & Sons, L.l.c. reported $9,307 in research payments for this study in 2025 (7 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Steven Y. Liu, M.D. Hematology & Oncology · Anchorage, AK
- Eric S. Schaefer, M.D. Hematology & Oncology · Rogers, AR
- Edgardo Santos, MD Hematology & Oncology · Fort Lauderdale, FL
- Peyman Haghighat, MD Medical Oncology · Meridian, ID
- Geetha Palaniappan, M.D. Internal Medicine · Papillion, NE
- Marjorie G. Zauderer, M.D. Medical Oncology · Hawthorne, NY
- Rachel E. Sanborn, MD Medical Oncology · Portland, OR
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Nebraska Cancer Specialists $2,305
- Alaska Oncology and Hematology $1,305
- Providence Portland Medical Center, OR $1,271
- Saint Luke's Mountain State Tumor Institute $1,178
- Westchester Medical Center $1,117
- Helios Clinical Research - Fort Lauderdale $1,079
- Highlands Oncology Group $1,052
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.